Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ANIP stock price vs REGN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at REGN's multiple
Needs Annual EPS, REGN P/E.
Implied fair value · at ANIP's multiple
Needs Annual EPS, ANIP P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ANI PHARMACEUTICALS INC · implied price per share
Reporting currency could not be verified.
REGENERON PHARMACEUTICALS, INC. · implied price per share
Reporting currency could not be verified.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
ANIP · not enough data.
REGN · not enough data.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
SUPERNUS PHARMACEUTICALS, INC.
ANIP vs SUPN
PERRIGO Co plc
ANIP vs PRGO
Viatris Inc
ANIP vs VTRS
Organon & Co.
ANIP vs OGN
TEVA PHARMACEUTICAL INDUSTRIES LTD
ANIP vs TEVA
AMGEN INC
ANIP vs AMGN
PFIZER INC
ANIP vs PFE
BRISTOL MYERS SQUIBB CO
ANIP vs BMY
BIOGEN INC.
ANIP vs BIIB
GILEAD SCIENCES, INC.
ANIP vs GILD
Seagate Technology Holdings plc
ANIP vs STX
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ANIP can sustain its 43.8% revenue growth while expanding margins toward REGN's level, then ANIP could be worth holding or adding because its EV-based multiples are lower than REGN's and it has a reasonable ROIC profile; if not, the -39.1% implied downside argues for caution.
ANIP is trading below REGN-implied valuation range and near the lower half of its own historical band, but the headline P/E comparison does not support a simple discount story because ANIP actually trades at a higher P/E than REGN. The market appears to be rewarding REGN's superior profitability and scale while giving ANIP credit for faster revenue growth and a lower P/S and EV-based multiple set.
Supporting Metrics
